Epitope hierarchy of spontaneous CD4+ T cell responses to LAGE-1

Journal of Immunology

Volumn 186, Issue 1, 2011, Pages 312-322

  Kudela, Pavol ^a   Sun, Zhaojun ^a   Fourcade, Julien ^a   Janjic, Bratislav ^a   Kirkwood, John M ^a   Maillere, Bernard ^b   Zarour, Hassane M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; EPITOPE; GAMMA INTERFERON; HLA DR ANTIGEN; LAGE 1 ANTIBODY; LAGE 1 ANTIGEN; NY ESO 1 ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADVANCED CANCER; AMINO TERMINAL SEQUENCE; ANTIBODY RESPONSE; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CD4+ T LYMPHOCYTE; CELL EXPANSION; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS REACTION; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNOMODULATION; IMMUNOSTIMULATION; MELANOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; TUMOR IMMUNITY;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; EPITOPES, T-LYMPHOCYTE; HUMANS; IMMUNODOMINANT EPITOPES; MELANOMA; MEMBRANE PROTEINS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTEIN BINDING;

EID: 79251566116     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1001989     Document Type: Article

References (26)

1. Chen, Y. T., M. J. Scanlan, U. Sahin, O. Türeci, A. O. Gure, S. Tsang, B. Williamson, E. Stockert, M. Pfreundschuh, and L. J. Old. 1997. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA 94: 1914-1918.
2. Uyttenhove, C., C. Godfraind, B. Lethé, A. Amar-Costesec, J. C. Renauld, T. F. Gajewski, M. T. Duffour, G. Warnier, T. Boon, and B. J. Van den Eynde. 1997. The expression of mouse gene P1A in testis does not prevent safe induction of cytolytic T cells against a P1A-encoded tumor antigen. Int. J. Cancer 70: 349-356.
3. Boon, T., P. G. Coulie, B. J. Van den Eynde, and P. van der Bruggen. 2006. Human T cell responses against melanoma. Annu. Rev. Immunol. 24: 175-208.
4. Lethé, B., S. Lucas, L. Michaux, C. De Smet, D. Godelaine, A. Serrano, E. De Plaen, and T. Boon. 1998. LAGE-1, a new gene with tumor specificity. Int. J. Cancer 76: 903-908.
5. + cancers. Proc. Natl. Acad. Sci. USA 97: 12198-12203.
6. Stockert, E., E. Jäger, Y. T. Chen, M. J. Scanlan, I. Gout, J. Karbach, M. Arand, A. Knuth, and L. J. Old. 1998. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. [see comments] J. Exp. Med. 187: 1349-1354.
7. + T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc. Natl. Acad. Sci. USA 98: 3964-3969.
8. + T cells from patients with NY-ESO-1-expressing melanoma. J. Immunol. 174: 1751-1759.
9. + T cells. Cancer Res. 62: 213-218.
10. + T cells. Cancer Res. 60: 4946-4952.
11. Sun, Z., B. Lethé, Y. Zhang, V. Russo, D. Colau, V. Stroobant, T. Boon, and P. van der Bruggen. 2006. A new LAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-A68 tumors. Cancer Immunol. Immunother. 55: 644-652.
12. + regulatory T cells and their ligands: implications for immunotherapy. Immunity 20: 107-118.
13. + T cells. Cancer Res. 63: 6506-6515.
14. Texier, C., S. Pouvelle, M. Busson, M. Hervé, D. Charron, A. Ménez, and B. Maillère. 2000. HLA-DR restricted peptide candidates for bee venom immunotherapy. J. Immunol. 164: 3177-3184. (Pubitemid 30148979)
15. Texier, C., S. Pouvelle-Moratille, C. Buhot, F. A. Castelli, C. Pecquet, A. Ménez, F. Leynadier, and B. Maillère. 2002. Emerging principles for the design of promiscuous HLA-DR-restricted peptides: an example from the major bee venom allergen. Eur. J. Immunol. 32: 3699-3707.
16. + T cell responses against TRAG-3 in patients with melanoma and breast cancers. J. Immunol. 177: 2717-2727.
17. + T cells against one immunodominant tumor-derived epitope in melanoma patients. J. Immunol. 179: 7932-7940.
18. + T cell expansion in melanoma patients. J. Immunol. 182: 5240-5249.
19. Fourcade, J., Z. Sun, P. Kudela, B. Janjic, J. M. Kirkwood, T. El-Hafnawy, and H. M. Zarour. 2010. Human tumor antigen-specific helper and regulatory T cells share common epitope specificity but exhibit distinct T cell repertoire. J. Immunol. 184: 6709-6718.
20. Sidney, J., H. M. Grey, S. Southwood, E. Celis, P. A. Wentworth, M. F. del Guercio, R. T. Kubo, R. W. Chesnut, and A. Sette. 1996. Definition of an HLAA3-like supermotif demonstrates the overlapping peptide-binding repertoires of common HLA molecules. Hum. Immunol. 45: 79-93.
21. + T cells by a single peptide with dual MHC class I and class II specificities: a new strategy for vaccine design. Cancer Res. 62: 3630-3635.
22. + T cell responses to tumor antigen NY-ESO-1. J. Immunol. 176: 5908-5917.
23. + T cell responses to SSX-4 in melanoma patients. J. Immunol. 174: 5092-5099.
24. + patients with renal cell carcinoma or melanoma. J. Exp. Med. 196: 619-628.
25. + T cell immunity is impaired in pancreatic carcinoma patients. J. Immunol. 181: 6595-6603.
26. Gnjatic, S., C. Wheeler, M. Ebner, E. Ritter, A. Murray, N. K. Altorki, C. A. Ferrara, H. Hepburne-Scott, S. Joyce, J. Koopman, et al. 2009. Seromic analysis of antibody responses in non-small cell lung cancer patients and healthy donors using conformational protein arrays. J. Immunol. Methods 341: 50-58.